Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow

Exelixis (NASDAQ: EXEL ) has done well marketing the multi-kinase inhibitor, cabozantinib, bringing in $1.81B in net product revenues in 2024. The party will one day end, however, as EXEL has already agreed to allow generics manufacturerScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: ...